Liu Y, Ye X J, Zhao C L, Ji Q
Department of Otolarynglogy,Tsinghua University Hospital,Beijing,100084,China.
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2016 Jul 5;30(13):1049-1052. doi: 10.13201/j.issn.1001-1781.2016.13.011.
To observe the effect of combined therapy on seasonal allergic rhinitis(AR) and quality of life.Ninety-six patients with severe seasonal AR unresponsive to intranasal corticosteroids alone were divided randomly into nasal budesonide group(group A),Nasal Budesonide combined with fexofenadine hydrochloride group(group B),and budesonide combined with montelukast group(group C).The symptom scores,Uni-VAS,and rhinoconjunctivitis quality of life(RQLQ) were evaluated 2 and 4 weeks after treatment initiation.In the group B and C,the symptom scores,Uni-VAS,and RQLQ were significantly lower than the group A(<0.05).As for nasal itching(after 2 weeks),rhinorrhea and sneezing,the symptom scores and Uni-VAS of group B were significantly lower than that of group C(<0.05).However,compared to group B,the improvement of nasal obstruction in group C was much better(<0.05).There was no significant difference in other symptoms and RQLQ.For patientswith severe seasonal AR unresponsive to intranasal corticosteroids alone,combined therapy can help alleviate clinical symptoms and improve quality of life.The combination of drugs should be individulized based on the severity of symptoms.
观察联合治疗对季节性变应性鼻炎（AR）及生活质量的影响。96例单独使用鼻用糖皮质激素治疗无效的重度季节性AR患者被随机分为布地奈德鼻喷雾剂组（A组）、布地奈德鼻喷雾剂联合盐酸非索非那定组（B组）和布地奈德联合孟鲁司特组（C组）。在开始治疗2周和4周后评估症状评分、单维视觉模拟量表（Uni-VAS）和变应性鼻炎生活质量问卷（RQLQ）。B组和C组的症状评分、Uni-VAS和RQLQ均显著低于A组（<0.05）。在鼻痒（2周后）、流涕和打喷嚏方面，B组的症状评分和Uni-VAS显著低于C组（<0.05）。然而，与B组相比，C组鼻塞的改善情况更好（<0.05）。其他症状和RQLQ方面无显著差异。对于单独使用鼻用糖皮质激素治疗无效的重度季节性AR患者，联合治疗有助于减轻临床症状并改善生活质量。应根据症状严重程度个体化选择联合用药。
